Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab

Ramon E. Flores-Gonzalez, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan, Silvia Delgado

Research output: Contribution to journalLetterpeer-review

3 Scopus citations

Abstract

We report the case of a MS patient on subcutaneous ofatumumab who became infected with SARS-CoV-2 and remained asymptomatic while developing antiviral IgM and IgG antibodies. The patient was B-cell depleted with normal serum immunoglobulin levels. Anti-SARS-CoV-2 IgG antibodies remained positive three months after the initial infection. These findings suggest that a MS patient treated with ofatumumab may be able to mount an effective humoral response to SARS-CoV-2 infection and probably to COVID-19 vaccines as well. Further research will be necessary to evaluate the humoral response of MS patients on ofatumumab to SARS-CoV-2 infection and COVID-19 vaccines.

Original languageEnglish (US)
Article number102777
JournalMultiple Sclerosis and Related Disorders
Volume49
DOIs
StatePublished - Apr 2021

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab'. Together they form a unique fingerprint.

Cite this